StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
50
This month
2
This week
1
This year
2
Publishing Date
2024 - 04 - 16
1
2024 - 04 - 09
1
2023 - 11 - 14
1
2023 - 11 - 07
1
2023 - 09 - 27
1
2023 - 08 - 17
1
2023 - 08 - 01
1
2023 - 07 - 24
1
2023 - 04 - 18
2
2023 - 03 - 15
1
2023 - 03 - 09
1
2023 - 02 - 01
1
2023 - 01 - 24
1
2023 - 01 - 23
1
2023 - 01 - 10
1
2023 - 01 - 05
1
2022 - 12 - 12
1
2022 - 12 - 07
1
2022 - 10 - 19
1
2022 - 10 - 18
1
2022 - 10 - 06
1
2022 - 09 - 14
1
2022 - 08 - 18
1
2022 - 08 - 01
1
2022 - 07 - 06
1
2022 - 06 - 14
1
2022 - 06 - 07
1
2022 - 06 - 02
1
2022 - 05 - 20
1
2022 - 05 - 10
1
2022 - 05 - 03
1
2022 - 04 - 29
1
2022 - 04 - 12
1
2022 - 04 - 05
1
2022 - 04 - 01
1
2022 - 03 - 30
1
2022 - 03 - 22
1
2022 - 03 - 15
1
2022 - 02 - 22
1
2022 - 02 - 15
1
2022 - 02 - 01
1
2022 - 01 - 18
1
2021 - 12 - 14
1
2021 - 12 - 01
1
2021 - 11 - 29
1
2021 - 11 - 15
1
2021 - 06 - 08
1
2020 - 12 - 22
1
2020 - 12 - 16
1
Sector
Finance
1
Health technology
50
Information
1
Tags
Acquisitions
1
Agreement
1
Application
2
Association
6
Bioconnect 2021 conference
1
Biomarker
1
Biotech
1
Biotech-beach
13
Biotechnology
2
Breast
2
Business
1
Cancer
19
Ceo
2
China
1
Clearance
1
Clinical-trials-phase-ii
1
Commercialization
1
Communications
1
Conference
8
Contract
1
Control
1
Covid
1
Designation
1
Diagnostic
5
Diagnostics
5
Direct
1
Disease
2
Distribution
1
Drug
4
Earnings
3
Ev
1
Events
3
Fastpack
2
Fda
1
Financial
4
Financial results
3
Food
2
Ipo
2
License
2
Meeting
9
N/a
56
Nasdaq
2
Negative
2
Offering
5
Pancreatic
4
Patent
2
People
3
Platform
4
Positive
3
Program
9
Qn-247
2
Qn-302
19
Research
11
Results
10
Technology
3
Therapeutics
50
Treatment
6
Trial
4
Tumors
4
Update
7
Entities
Abbvie inc.
88
Abeona therapeutics inc.
73
Adc therapeutics sa
82
Agile therapeutics, inc.
61
Akebia therapeutics, inc.
67
Akero therapeutics, inc.
63
Aldeyra therapeutics, inc.
58
Aligos therapeutics, inc.
57
Allogene therapeutics, inc.
86
Altamira therapeutics ltd
55
Alterity therapeutics limited
74
Amgen inc.
69
Amicus therapeutics, inc.
56
Amplitude healthcare acquisition corp
59
Aquestive therapeutics, inc.
82
Astrazeneca plc
69
Axsome therapeutics, inc.
79
Bioxcel therapeutics, inc.
62
Brainstorm cell therapeutics inc.
57
Cidara therapeutics, inc.
61
Cognition therapeutics inc
79
Crispr therapeutics ag
61
Cytomx therapeutics, inc.
64
Eli lilly and company
138
Fortress biotech, inc.
73
Fulcrum therapeutics, inc.
74
G1 therapeutics, inc.
81
Glaxosmithkline plc
82
Horizon therapeutics public limited company
74
Hoth therapeutics, inc.
68
Inhibikase therapeutics, inc.
66
Intellia therapeutics, inc.
56
Johnson & johnson
186
Kymera therapeutics, inc.
64
Morgan stanley
147
Novartis ag
114
Nurix therapeutics, inc.
61
Omega therapeutics inc
55
Oncternal therapeutics, inc.
57
Orange
66
Outlook therapeutics, inc.
71
Pliant therapeutics, inc.
70
Plus therapeutics, inc.
84
Poseida therapeutics, inc.
60
Ptc therapeutics, inc.
57
Relief therapeutics holding sa
80
Sanofi
342
Sarepta therapeutics, inc.
72
Seres therapeutics, inc.
62
Spero therapeutics, inc.
70
Springworks therapeutics, inc.
58
Teva pharmaceutical industries ltd
64
Tg therapeutics, inc.
88
Transcode therapeutics inc
68
Travere therapeutics inc.
79
Trevi therapeutics, inc.
55
Tscan therapeutics inc
64
Vera therapeutics inc - class a
55
Vivos therapeutics inc
56
Voyager therapeutics, inc.
74
Symbols
BMO
1
CEMI
1
LLY
1
MRZM
1
PFE
1
QLGN
50
VKTX
1
Exchanges
Nasdaq
50
Nyse
1
Crawled Date
2024 - 04 - 16
1
2024 - 04 - 09
1
2023 - 11 - 14
1
2023 - 11 - 07
1
2023 - 09 - 27
1
2023 - 08 - 17
1
2023 - 08 - 01
1
2023 - 07 - 24
1
2023 - 04 - 18
2
2023 - 03 - 15
1
2023 - 03 - 09
1
2023 - 02 - 01
1
2023 - 01 - 24
1
2023 - 01 - 23
1
2023 - 01 - 10
1
2023 - 01 - 05
1
2022 - 12 - 12
1
2022 - 12 - 07
1
2022 - 10 - 19
1
2022 - 10 - 18
1
2022 - 10 - 06
1
2022 - 09 - 14
1
2022 - 08 - 18
1
2022 - 08 - 01
1
2022 - 07 - 06
1
2022 - 06 - 14
1
2022 - 06 - 07
1
2022 - 06 - 02
1
2022 - 05 - 20
1
2022 - 05 - 10
1
2022 - 05 - 03
1
2022 - 04 - 29
1
2022 - 04 - 12
1
2022 - 04 - 05
1
2022 - 04 - 01
1
2022 - 03 - 30
1
2022 - 03 - 22
1
2022 - 03 - 15
1
2022 - 02 - 22
1
2022 - 02 - 15
1
2022 - 02 - 01
1
2022 - 01 - 18
1
2021 - 12 - 14
1
2021 - 12 - 01
1
2021 - 11 - 29
1
2021 - 11 - 15
1
2021 - 06 - 08
1
2020 - 12 - 22
1
2020 - 12 - 16
1
Crawled Time
11:00
1
12:00
4
12:20
1
13:00
4
13:20
10
13:30
2
14:00
3
14:20
5
14:30
4
15:00
3
16:00
5
17:00
1
20:00
3
21:00
2
22:00
2
Source
www.biospace.com
17
www.globenewswire.com
33
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Therapeutics
entities :
Qualigen therapeutics, inc.
save search
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
Published:
2024-04-16
(Crawled : 11:00)
- globenewswire.com
MRZM
|
$0.095
1031.22%
2.2K
|
Information
|
72.73%
|
O:
0.0%
H:
72.73%
C:
72.73%
QLGN
|
$0.3117
4.81%
-2.2%
27K
|
Health Technology
|
-7.98%
|
O:
-4.91%
H:
3.23%
C:
-3.29%
for
commercialization
therapeutics
agreement
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Published:
2024-04-09
(Crawled : 12:00)
- globenewswire.com
QLGN
|
$0.3117
4.81%
-2.2%
27K
|
Health Technology
|
-22.6%
|
O:
3.2%
H:
0.0%
C:
-0.28%
qn-302
association
positive
cancer
research
meeting
therapeutics
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
Published:
2023-11-14
(Crawled : 22:00)
- globenewswire.com
QLGN
|
$0.3117
4.81%
-2.2%
27K
|
Health Technology
|
-59.18%
|
O:
4.76%
H:
0.0%
C:
-4.55%
update
therapeutics
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
Published:
2023-11-07
(Crawled : 14:00)
- globenewswire.com
QLGN
|
$0.3117
4.81%
-2.2%
27K
|
Health Technology
|
-57.14%
|
O:
2.86%
H:
4.17%
C:
0.38%
qn-302
tumors
treatment
trial
therapeutics
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023
Published:
2023-09-27
(Crawled : 14:30)
- biospace.com/
QLGN
|
$0.3117
4.81%
-2.2%
27K
|
Health Technology
|
-71.15%
|
O:
0.96%
H:
0.0%
C:
-1.9%
qn-302
cancer
pancreatic
therapeutics
Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors
Published:
2023-08-17
(Crawled : 12:00)
- globenewswire.com
QLGN
|
$0.3117
4.81%
-2.2%
27K
|
Health Technology
|
-71.7%
|
O:
-0.94%
H:
0.0%
C:
-1.83%
qn-302
tumors
treatment
therapeutics
Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
Published:
2023-08-01
(Crawled : 12:00)
- globenewswire.com
QLGN
|
$0.3117
4.81%
-2.2%
27K
|
Health Technology
|
-73.45%
|
O:
10.62%
H:
0.8%
C:
-9.6%
qn-302
fda
tumors
treatment
clearance
trial
therapeutics
Qualigen Therapeutics Divests FastPack® Diagnostics Business
Published:
2023-07-24
(Crawled : 12:20)
- globenewswire.com
QLGN
|
$0.3117
4.81%
-2.2%
27K
|
Health Technology
|
-71.15%
|
O:
0.48%
H:
0.0%
C:
-0.48%
fastpack
business
diagnostics
therapeutics
Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL
Published:
2023-04-18
(Crawled : 13:00)
- globenewswire.com
QLGN
|
$0.3117
4.81%
-2.2%
27K
|
Health Technology
|
-70.15%
|
O:
0.5%
H:
3.16%
C:
-5.95%
qn-302
association
cancer
research
meeting
therapeutics
Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL
Published:
2023-04-18
(Crawled : 12:00)
- biospace.com/
QLGN
|
$0.3117
4.81%
-2.2%
27K
|
Health Technology
|
-70.15%
|
O:
0.5%
H:
3.16%
C:
-5.95%
qn-247
breast
association
cancer
research
meeting
therapeutics
negative
Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023
Published:
2023-03-15
(Crawled : 13:20)
- globenewswire.com
QLGN
|
$0.3117
4.81%
-2.2%
27K
|
Health Technology
|
-70.87%
|
O:
4.85%
H:
0.0%
C:
-6.48%
research
meeting
association
therapeutics
cancer
Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference
Published:
2023-03-09
(Crawled : 15:00)
- globenewswire.com
QLGN
|
$0.3117
4.81%
-2.2%
27K
|
Health Technology
|
-74.36%
|
O:
-1.71%
H:
2.61%
C:
-1.23%
conference
association
program
therapeutics
cancer
Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders
Published:
2023-02-01
(Crawled : 14:20)
- globenewswire.com
QLGN
|
$0.3117
4.81%
-2.2%
27K
|
Health Technology
|
-76.74%
|
O:
1.47%
H:
13.07%
C:
9.25%
therapeutics
Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302
Published:
2023-01-24
(Crawled : 14:20)
- biospace.com/
QLGN
|
$0.3117
4.81%
-2.2%
27K
|
Health Technology
|
-76.56%
|
O:
3.13%
H:
0.0%
C:
-3.03%
qn-302
therapeutics
Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications
Published:
2023-01-23
(Crawled : 14:20)
- globenewswire.com
QLGN
|
$0.3117
4.81%
-2.2%
27K
|
Health Technology
|
-76.19%
|
O:
3.97%
H:
0.0%
C:
-2.29%
communications
diagnostics
therapeutics
Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer
Published:
2023-01-10
(Crawled : 16:00)
- biospace.com/
QLGN
|
$0.3117
4.81%
-2.2%
27K
|
Health Technology
|
-76.38%
|
O:
20.47%
H:
3.92%
C:
-12.42%
qn-302
designation
drug
therapeutics
food
cancer
pancreatic
Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform
Published:
2023-01-05
(Crawled : 20:00)
- biospace.com/
QLGN
|
$0.3117
4.81%
-2.2%
27K
|
Health Technology
|
-78.2%
|
O:
-0.44%
H:
10.21%
C:
10.21%
disease
diagnostic
therapeutics
update
platform
Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
Published:
2022-12-12
(Crawled : 14:00)
- biospace.com/
QLGN
|
$0.3117
4.81%
-2.2%
27K
|
Health Technology
|
-79.73%
|
O:
0.67%
H:
4.03%
C:
-2.34%
nasdaq
therapeutics
Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors
Published:
2022-12-07
(Crawled : 14:20)
- globenewswire.com
QLGN
|
$0.3117
4.81%
-2.2%
27K
|
Health Technology
|
-81.37%
|
O:
0.0%
H:
0.62%
C:
-6.21%
qn-302
treatment
drug
therapeutics
food
tumors
Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute
Published:
2022-10-19
(Crawled : 13:00)
- globenewswire.com
QLGN
|
$0.3117
4.81%
-2.2%
27K
|
Health Technology
|
-89.13%
|
O:
-3.01%
H:
4.59%
C:
-1.76%
program
therapeutics
cancer
← Previous
1
2
3
Next →
Gainers vs Losers
59%
41%
Top 10 Gainers
AGBA
|
News
|
$1.03
157.5%
57.94%
120M
|
Finance
ZCMD
|
$1.45
5.84%
52.1%
2.3M
|
Commercial Services
INVO
|
$1.52
100.0%
51.13%
5M
|
Health Technology
ISPC
|
$0.421
97.65%
49.53%
37M
|
Professional, Scientific, and T...
WLGS
|
News
|
$0.5
45.65%
470K
|
OST
|
$0.509
23.81%
45.26%
90K
|
GDHG
|
$0.263
21.76%
40.66%
3.1M
|
XPON
|
News
|
$3.15
63.21%
37.74%
16M
|
TIRX
|
$0.8
65.02%
30.74%
58M
|
BNTC
|
News
|
$6.82
42.08%
30.64%
3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.